查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983984

勃起功能障礙治療設備市場：2026-2032年全球市場預測（依產品類型、適應症、年齡層、材質、作用機制、電源、最終用戶和通路分類）

Erectile Dysfunction Devices Market by Product Type, Indication, Age Group, Material Type, Mechanism of Action, Power Source, End-User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，勃起功能障礙治療設備市場價值將達到 18.1 億美元，到 2026 年將成長至 19.3 億美元，到 2032 年將達到 28 億美元，複合年成長率為 6.38%。

主要市場統計數據
基準年 2025 18.1億美元
預計年份：2026年 19.3億美元
預測年份 2032 28億美元
複合年成長率 (%) 6.38%

對當前勃起功能障礙治療設備市場進行全面概述，重點關注技術進步、相關人員的需求以及不斷發展的患者照護路徑。

引言部分將當前勃起功能障礙治療設備的現狀置於快速的臨床創新、醫保報銷模式的轉變以及患者對微創解決方案日益成長的期望等背景下進行闡述。近年來，技術進步拓展了治療選擇，使其不再局限於以藥物為主的一線療法，而是擴展到植入式解決方案、增強性功能的輔助設備以及非侵入性治療方法。這些發展與以病人為中心的照護路徑日益受到重視的趨勢相吻合，而這種路徑的驅動力在於便利性、隱藏性和生活品質的提升。

臨床創新、監管改革和不斷變化的分銷管道動態如何相互交織，重新定義整個勃起功能障礙治療生態系統的價值創造。

該領域的變革性變化是由臨床、技術和市場因素的整合所驅動的，這些因素正在重新定義價值創造。在臨床上，微創和可逆治療方法的興起提升了低強度脈衝超音波和衝擊波療法等治療設備的重要性。這些設備提供了非手術治療途徑，並擴大了目標患者群體。同時，植入設計的創新，包括對充氣式和半剛性植入的改進，正優先考慮可靠性、易於植入性和患者舒適度。這些技術升級越來越受到彈性體聚合物、矽膠、金屬合金（如不銹鋼和鈦）以及兼顧生物相容性和機械功能的聚氨酯配方等材料科學進步的影響。

評估美國於 2025 年實施的關稅對醫療設備供應鏈和定價策略的累積營運、商業和採購影響。

2025年推出的定向關稅措施迫使相關人員重新思考其供應鏈結構、籌資策略和成本轉嫁機制。尤其是依賴跨境零件的精密植入和電子治療設備製造商，正面臨原物料成本飆升和物流複雜性增加的雙重挑戰。為應對這些挑戰，許多製造商正在探索諸如回流、近岸外包或多源採購等方法，以降低關稅風險，同時確保品管和合規性。擁有一體化製造地和完善品管系統的策略供應商在吸收和管理關稅波動方面具有優勢，且不會影響產品的連續性。

細分市場洞察：產品差異化、適應症的複雜性、人口統計因素、材料選擇、機制選擇以及分銷管道對策略定位的影響。

市場區隔洞察凸顯了產品差異化的多面性，以及研發和商業化與臨床及終端用戶需求保持一致的重要性。按產品類型分類，市場包括陰莖植入、輔助器具、治療裝置和真空收縮裝置。陰莖植入本身又分為植入，兩者在機械複雜性、病患滿意度和手術訓練要求之間各有重點。支撐裝置分為夾式和環式壓迫裝置，與植入相比，它們通常定位為輔助或微創方案。治療裝置包括低強度超音波設備和衝擊波治療裝置，這些裝置提供非植入式、以再生醫學為重點的治療方法，旨在治療潛在的血管和組織疾病。

美洲、歐洲、中東和非洲以及亞太地區的區域績效和策略挑戰：說明實施趨勢、償還趨勢和供給側考量。

區域趨勢差異顯著，美洲、歐洲、中東和非洲以及亞太地區需要不同的商業性和監管策略。在美洲，完善的報銷體系和強大的醫院主導治療基礎正在推動更複雜的植入式解決方案的普及，尤其是在那些治療效果穩定、臨床醫生技能水平高，從而降低了應用門檻的地區。同時，面向消費者的銷售管道和對非侵入性治療方法日益成長的需求正在擴大門診和居家醫療的目標患者群體。這為那些既能減輕治療負擔又能維持臨床療效的價值提案創造了空間。

成熟製造商、創新專家和分銷合作夥伴之間的競爭和企業策略，推動產品系列、市場進入和臨床部署。

競爭動態呈現出成熟醫療設備製造商、專業創新企業和新興技術供應商並存的態勢。主要企業透過結合臨床證據、豐富的產品系列和通路夥伴關係，在核心市場保持發展勢頭。關鍵的企業策略包括：迭代式產品開發以降低手術複雜性；材料創新以提高生物相容性和耐久性；以及透過有針對性的研究者主導試驗和真實世界臨床結果註冊研究來培養臨床專家。

為製造商、臨床醫生和通路合作夥伴提供具體且優先的建議，以加速臨床應用、增強市場進入並降低商業性風險。

產業領導企業應優先考慮一系列切實可行的舉措，將洞察轉化為可衡量的商業性成果。首先，投資於比較性臨床證據和真實世界註冊研究，以證明器械在主要適應症、次要適應症和混合適應症中的耐用性、功能性結果和併發症情況。此類證據對於說服支付方和臨床醫生以及在醫院採購流程中區分不同器械至關重要。其次，實現生產和供應商網路多元化，以降低關稅波動和單一來源依賴的風險，同時記錄監管申報所需的追溯性和品管系統。

為了支持醫療設備市場的深入洞察，我們開發了一種高度透明的調查方法，詳細說明了資料來源、專家檢驗、分析框架、情境測試和已知的限制。

本分析的調查方法結合了原始資料和二手資料的收集、結構化的分析框架以及臨床和商業專家的迭代檢驗。原始資料透過訪談醫療保健專業人員、採購經理、分銷商和技術開發人員收集，以獲取有關醫療設備效能、推廣障礙和分銷管道趨勢的第一手資訊。二手資料來源包括同行評審的臨床文獻、監管指導文件、材料科學研究和公開的政策分析，以全面檢驗臨床和安全證據。

為了支援經營團隊決策、投資決策和產品藍圖制定，我們整合並總結了市場促進因素、結構性風險和策略重點。

總之，勃起功能障礙治療器材市場正處於轉折點，不斷發展的臨床創新、材料科學、監管務實性和分銷管道共同構成了策略挑戰。能夠整合可靠的實證醫學證據、強大的生產能力和客製化分銷策略的製造商，將更有利於把產品創新轉化為永續的商業性成功。充分考慮患者偏好、人口趨勢以及每種適應症的具體需求，將進一步提升產品市場契合度，並創造差異化的價值提案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 勃起功能障礙治療器材市場：依產品類型分類

  • 陰莖植入
    • 可擴張植入
    • 半剛性植入
  • 支援設備
    • 夾鉗式裝置
    • 環形壓縮裝置
  • 治療設備
    • 低強度脈衝超音波設備
    • 衝擊波治療設備
  • 真空約束裝置

第9章：勃起功能障礙治療器材市場：依適應症分類

  • 混合型勃起功能障礙
    • 與老齡化相關的因素
    • 多種原因
  • 原發性功能障礙
    • 神經系統因素
    • 血管因素
  • 續發性功能障礙
    • 荷爾蒙因素
    • 心理因素

第10章：勃起功能障礙治療設備市場：依年齡層別分類

  • 18-40歲
  • 41-60歲
  • 61歲或以上

第11章 勃起功能障礙治療器材市場：依材料類型分類

  • 彈性體
  • 金屬
    • 不銹鋼
    • 鈦
  • 聚氨酯
  • 矽酮

第12章 勃起功能障礙治療器材市場：依作用機轉分類

  • 油壓裝置
  • 機械操作裝置

第13章 按電源分類的勃起功能障礙治療設備市場

  • 電池供電
  • 手動輸入

第14章 勃起功能障礙治療設備市場：依最終使用者分類

  • 家庭醫療保健
  • 醫院
  • 專科診所

第15章 勃起功能障礙治療器材市場：依通路分類

  • 線上平台
  • 零售藥房
  • 專業零售店
    • 醫療設備商店
    • 外科醫療用品商店

第16章 勃起功能障礙治療器材市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 勃起功能障礙治療器材市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 勃起功能障礙治療器材市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 美國勃起功能障礙治療設備市場

第20章 中國勃起功能障礙治療器材市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advin Health Care
  • Alma Lasers Ltd.
  • Augusta Medical Systems LLC
  • Boston Scientific Corporation
  • Coloplast A/S
  • Comphya SA
  • DirexGroup
  • Dornier MedTech GmbH
  • Futura Medical Developments Limited
  • G.SURGIWEAR LTD.
  • Implantica Management AG
  • Medispec Ltd.
  • OHHMED Medical Ltd.
  • Owen Mumford Limited
  • PROMEDON GmbH
  • Rigicon, Inc.
  • STORZ MEDICAL AG
  • TE Inc.
  • TIMM Medical
  • Vacurect
  • Zimmer MedizinSysteme GmbH
  • ZSI Surgical Implants SRL
Product Code: MRR-1730A405FA49

The Erectile Dysfunction Devices Market was valued at USD 1.81 billion in 2025 and is projected to grow to USD 1.93 billion in 2026, with a CAGR of 6.38%, reaching USD 2.80 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.81 billion
Estimated Year [2026] USD 1.93 billion
Forecast Year [2032] USD 2.80 billion
CAGR (%) 6.38%

Comprehensive overview of the current erectile dysfunction device landscape highlighting technological progress, stakeholder needs, and evolving patient care pathways

The introduction situates the current erectile dysfunction device landscape within a context of rapid clinical innovation, shifting reimbursement paradigms, and amplified patient expectations for minimally invasive solutions. Over recent years, technological advances have expanded the therapeutic toolkit beyond pharmacologic first-line therapies, creating room for implantable solutions, supportive devices that enhance sexual function, and noninvasive therapeutic modalities. These developments have coincided with a rising emphasis on patient-centered pathways, where convenience, discreet use, and quality-of-life outcomes drive adoption.

Stakeholders across clinical, manufacturing, and distribution channels are navigating a dynamic environment in which regulatory clarity and payor policies increasingly influence product design and go-to-market strategies. Clinicians are scrutinizing evidence of durability, complication rates, and functional outcomes, while procurement teams balance device performance with inventory and training costs. At the same time, patients are more engaged in treatment selection, valuing devices that align with lifestyle preferences and have transparent safety profiles. Against this backdrop, the market is differentiating along several dimensions including device mechanism, material composition, power source, and end-user context, all of which shape adoption patterns and competitive positioning.

This introductory synthesis establishes the imperative for manufacturers and investors to align clinical evidence, design innovation, and commercial execution. By connecting product attributes to real-world clinical pathways and distribution realities, organizations can better prioritize R&D resources and market entry tactics that resonate with both clinicians and patients.

How clinical innovation, regulatory recalibration, and shifting channel dynamics are converging to redefine value creation across the erectile dysfunction device ecosystem

Transformative shifts in this segment are driven by a convergence of clinical, technological, and market forces that are redefining value creation. Clinically, the movement toward minimally invasive and reversible solutions has elevated the importance of therapeutic devices such as low-intensity pulsed ultrasound and shockwave therapy, which offer non-surgical pathways and an expanded addressable patient base. Concurrently, innovations in implant design, including refinements in inflatable and semi-rigid implants, have prioritized reliability, ease of implantation, and patient comfort. These technical upgrades are increasingly influenced by material science advances across elastomeric polymers, silicones, metallic alloys such as stainless steel and titanium, and polyurethane formulations that balance biocompatibility with mechanical function.

From a regulatory and reimbursement perspective, clearer evidence thresholds and value-based procurement discussions are prompting manufacturers to generate comparative effectiveness and durability data earlier in development. This shift favors companies that can demonstrate meaningful outcomes across primary, secondary, and mixed indications, including aging-related, neurological, vascular, hormonal, and psychogenic etiologies. At the same time, distribution and channel evolution is reshaping access models: online platforms are lowering barriers to consumer engagement, while traditional specialist retailers and hospital procurement systems maintain their role for complex devices and procedures. Together, these dynamics are encouraging strategic partnerships between device makers, clinical stakeholders, and distribution partners to accelerate adoption while controlling cost and complexity.

In essence, the landscape is moving from product-centric propositions to integrated care solutions where evidence, usability, and channel strategy converge to determine commercial success.

Assessing the cumulative operational, commercial, and procurement impacts of United States tariffs implemented during 2025 on device supply chains and pricing strategies

The introduction of targeted tariff measures in 2025 has prompted stakeholders to reassess supply chain architecture, sourcing strategies, and cost pass-through dynamics. Manufacturers reliant on cross-border components, particularly for precision-engineered implants and electronic therapeutic devices, have faced elevated input costs and logistical complexity. In response, several manufacturing organizations are evaluating reshoring, nearshoring, or multi-sourcing approaches to mitigate tariff exposure while preserving quality control and regulatory compliance. Strategic suppliers with integrated manufacturing footprints and established quality systems have an advantage in absorbing or managing tariff volatility without compromising product continuity.

Beyond manufacturing, tariffs have influenced channel economics and pricing strategies. Retailers and specialty distributors have needed to balance margin pressures with competitive positioning, leading some to renegotiate supplier contracts or consolidate SKUs to maintain inventory turnover and price stability. Hospitals and specialty clinics are recalibrating procurement criteria to emphasize total cost of ownership and long-term service agreements, rather than unit price alone, to shield budgets from episodic tariff-driven spikes. Additionally, the policy environment has accelerated dialogues around bilateral supplier agreements and strategic inventory buffers to ensure continuity of care for elective procedures.

Critically, the tariff environment has reinforced the importance of transparent supplier traceability and component provenance for regulatory submissions. Companies that proactively document supply chain resilience, implement dual-sourcing strategies, and communicate cost management plans to payors and procurement stakeholders are better positioned to navigate uncertainty and preserve market access.

Segment-driven insights revealing product differentiation, indication complexity, demographic drivers, material selection, mechanism choices, and channel implications for strategic positioning

Segmentation insights reveal the multifaceted nature of product differentiation and the importance of aligning R&D and commercialization with clinical and end-user needs. When evaluating products by type, the landscape encompasses penile implants, supportive devices, therapeutic devices, and vacuum constriction devices. Penile implants themselves bifurcate into inflatable implants and semi-rigid implants, each presenting distinct trade-offs between mechanical complexity, patient satisfaction, and surgical training requirements. Supportive devices are categorized into clamping devices and ring constriction devices, which are generally positioned as adjunctive or less invasive options relative to implants. Therapeutic devices include low-intensity pulsed ultrasound devices and shockwave therapy devices that offer non-implantable, regenerative-focused modalities targeting underlying vascular or tissue conditions.

Indication-based segmentation adds further nuance. The market must be understood across mixed erectile dysfunction, primary erectile dysfunction, and secondary erectile dysfunction. Mixed erectile dysfunction frequently involves aging-related causes as well as combination etiologies that require blended treatment pathways. Primary erectile dysfunction is often driven by neurological and vascular causes that necessitate different therapeutic intensities and evidence thresholds. Secondary erectile dysfunction encompasses hormonal and psychogenic causes where device strategies often intersect with pharmacologic and behavioral interventions. Age group stratification-encompassing younger adult populations, middle-aged cohorts, and those 61 years and above-informs product positioning, tolerance for invasiveness, and expectations around longevity and maintenance.

Material and mechanism considerations are central to device performance and regulatory review. Material types span elastomeric polymers, metallic materials such as stainless steel and titanium, polyurethane, and silicone, each bringing distinct biocompatibility and mechanical properties to bear. Mechanisms of action contrast hydraulic action devices with mechanical action devices, and power-source differentiation between battery-powered and manual units affects usability, maintenance, and clinical support requirements. Finally, end-user context and distribution channel dynamics-home healthcare, hospitals, specialty clinics, online platforms, retail pharmacies, and specialist retailers including medical device stores and surgical supply stores-shape adoption pathways, training needs, and post-market support obligations. Synthesizing these segmentation layers highlights opportunities for targeted innovation and tailored commercial strategies that reflect clinical realities and patient preferences.

Regional performance and strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific highlighting adoption trends, reimbursement dynamics, and supply considerations

Regional dynamics vary substantially and mandate differentiated commercial and regulatory strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established reimbursement frameworks and a strong hospital-driven procedural base favor higher-complexity implantable solutions, particularly where durable outcomes and clinician familiarity reduce adoption friction. At the same time, direct-to-consumer channels and an increasing appetite for noninvasive therapeutic options are expanding the addressable patient base in ambulatory and home settings. This creates room for value propositions that reduce procedural burden while preserving clinical efficacy.

In Europe, Middle East & Africa, heterogeneous reimbursement landscapes and variable regulatory pathways require companies to localize evidence generation and pricing strategies. Some markets within this region have progressive reimbursement mechanisms that support innovative therapeutic devices when robust health-economic evidence is presented, while others remain price-sensitive and prefer lower-complexity devices with predictable cost profiles. Across procurement systems and clinical practice patterns, partnerships with regional distributors and clinical opinion leaders are instrumental in building credibility and facilitating market access.

Asia-Pacific presents a blend of rapid adoption among higher-income markets and rising demand in emerging economies. In many Asia-Pacific markets, the interplay between expanding private healthcare delivery and growing consumer healthcare literacy creates opportunities for both implantable and noninvasive devices. Nevertheless, manufacturers must navigate diverse regulatory requirements, local manufacturing expectations, and differing clinical practice patterns. Across all regions, strategic alignment between clinical evidence, reimbursement positioning, and distribution networks will determine the pace and scale of adoption.

Competitive dynamics and corporate strategies among established manufacturers, specialist innovators, and distribution partners that drive product portfolios, market entry, and clinical adoption

Competitive dynamics reflect a mixture of established medical device manufacturers, specialist innovators, and emerging technology providers. Leading companies leverage a combination of clinical evidence generation, product portfolio breadth, and channel partnerships to maintain traction in core markets. Key corporate strategies include iterative product development to reduce procedural complexity, material innovations that improve biocompatibility and longevity, and the cultivation of clinical champions through targeted investigator-initiated studies and real-world outcome registries.

Strategic collaborations and licensing agreements are common as firms seek to complement internal capabilities with external expertise in materials science, electronics, and therapeutic energy modalities. Companies that can integrate post-market service models-such as training programs, surgeon support, and product warranties-create sustainable differentiation that extends beyond the initial sale. Additionally, distribution strategies that blend direct hospital engagement with specialist retail and online channels improve access across diverse end-user contexts.

Mergers, acquisitions, and minority investments continue to be tools for capability acquisition and accelerated market entry, particularly when novel therapeutic mechanisms or digital health add-ons are involved. Firms that maintain transparency around clinical outcomes, invest in payer engagement, and adapt manufacturing footprints in response to trade policy shifts will likely secure competitive advantage. Ultimately, corporate success will be determined by the ability to align innovation pipelines with pragmatic commercialization plans and resilient supply chain architectures.

Practical and prioritized recommendations for manufacturers, clinicians, and channel partners to accelerate clinical adoption, strengthen market access, and mitigate commercial risk

Industry leaders should prioritize a set of pragmatic actions to convert insights into measurable commercial outcomes. First, invest in comparative clinical evidence and real-world registries that demonstrate device durability, functional outcomes, and complication profiles across primary, secondary, and mixed indications. Such evidence will be critical for convincing payors and clinicians, and for differentiating devices within hospital procurement processes. Second, diversify manufacturing and supplier networks to reduce exposure to tariff volatility and single-source dependencies, while documenting traceability and quality systems for regulatory submissions.

Third, tailor product portfolios and commercialization plans to specific demographic and clinical segments, recognizing that age group, etiology of dysfunction, and end-user setting materially influence device selection. Simultaneously, optimize material and mechanism choices to balance performance, cost, and regulatory risk. Fourth, develop hybrid channel strategies that combine hospital partnerships for complex procedures with online platforms and specialist retailers for less invasive solutions and patient education. Fifth, engage early with payors and health technology assessment bodies to align evidence generation with reimbursement criteria and to explore innovative payment models that reflect long-term value rather than upfront cost alone.

Finally, build adaptive commercial models that integrate clinician training, warranty and service offerings, and digital support tools to improve procedural outcomes and patient satisfaction. These steps will strengthen product positioning, reduce commercial friction, and accelerate sustainable adoption.

Transparent research methodology detailing data sources, expert validation, analytical frameworks, scenario testing, and acknowledged limitations to underpin robust device market insights

The research methodology underpinning this analysis combines primary and secondary data collection, a structured analytical framework, and iterative validation with clinical and commercial experts. Primary inputs include interviews with clinicians, procurement leaders, distributors, and technology developers to capture experiential insights on device performance, adoption barriers, and channel dynamics. Secondary sources comprise peer-reviewed clinical literature, regulatory guidance documents, materials science research, and publicly available policy analyses to triangulate clinical and safety evidence.

Analytical methods include segmentation mapping across product, indication, demographic, material, mechanism, power source, end-user, and distribution dimensions to identify high-opportunity intersections. Scenario analysis is used to stress-test supply chain and tariff impacts on operational continuity and procurement behavior. The methodology emphasizes transparency in assumptions, with sensitivity analyses performed where conclusions depend on variable inputs. Findings were iteratively validated with independent clinical advisors and industry practitioners to ensure practical relevance and to refine interpretive judgments.

Limitations of the methodology are acknowledged, including the variability of regional reimbursement environments and the evolving nature of clinical evidence for newer therapeutic modalities. Where appropriate, the report highlights data gaps and recommends priority evidence-generation activities to strengthen future assessments.

Concluding synthesis of market drivers, structural risks, and strategic priorities to inform executive decision-making, investment choices, and product roadmaps

In conclusion, the erectile dysfunction device landscape is at an inflection point where clinical innovation, material science, regulatory pragmatism, and channel evolution collectively shape strategic imperatives. Manufacturers that integrate robust evidence-generation with resilient manufacturing footprints and tailored channel strategies will be best placed to convert product innovation into sustainable commercial success. Attention to patient preferences, demographic trends, and indication-specific needs will further refine product-market fit and drive differentiated value propositions.

Regulatory clarity and payer engagement remain critical enablers for widespread adoption, particularly for higher-complexity implantable solutions and novel therapeutic modalities. The tariff environment and shifting distribution economics underscore the necessity for flexible supply chain architectures and transparent cost management strategies. Ultimately, success in this market will hinge on the ability to align clinical proof, operational resilience, and go-to-market execution in a way that delivers demonstrable outcomes for patients and predictable value for healthcare systems.

Organizations that adopt a disciplined, evidence-led approach to product development and commercialization will unlock opportunities across diverse geographies and care settings, positioning themselves for long-term leadership in a rapidly evolving therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Erectile Dysfunction Devices Market, by Product Type

  • 8.1. Penile Implants
    • 8.1.1. Inflatable Implants
    • 8.1.2. Semi-Rigid Implants
  • 8.2. Supportive Devices
    • 8.2.1. Clamping Devices
    • 8.2.2. Ring Constriction Devices
  • 8.3. Therapeutic Devices
    • 8.3.1. Low-Intensity Pulsed Ultrasound Devices
    • 8.3.2. Shockwave Therapy Devices
  • 8.4. Vacuum Constriction Devices

9. Erectile Dysfunction Devices Market, by Indication

  • 9.1. Mixed Erectile Dysfunction
    • 9.1.1. Aging-Related Causes
    • 9.1.2. Combination Causes
  • 9.2. Primary Erectile Dysfunction
    • 9.2.1. Neurological Causes
    • 9.2.2. Vascular Causes
  • 9.3. Secondary Erectile Dysfunction
    • 9.3.1. Hormonal Causes
    • 9.3.2. Psychogenic Causes

10. Erectile Dysfunction Devices Market, by Age Group

  • 10.1. 18-40 Years
  • 10.2. 41-60 Years
  • 10.3. 61 Years And Above

11. Erectile Dysfunction Devices Market, by Material Type

  • 11.1. Elastomeric
  • 11.2. Metallic
    • 11.2.1. Stainless Steel
    • 11.2.2. Titanium
  • 11.3. Polyurethane
  • 11.4. Silicone

12. Erectile Dysfunction Devices Market, by Mechanism of Action

  • 12.1. Hydraulic Action Devices
  • 12.2. Mechanical Action Devices

13. Erectile Dysfunction Devices Market, by Power Source

  • 13.1. Battery-Powered
  • 13.2. Manual

14. Erectile Dysfunction Devices Market, by End-User

  • 14.1. Home Healthcare
  • 14.2. Hospitals
  • 14.3. Specialty Clinics

15. Erectile Dysfunction Devices Market, by Distribution Channel

  • 15.1. Online Platforms
  • 15.2. Retail Pharmacies
  • 15.3. Specialist Retailers
    • 15.3.1. Medical Device Stores
    • 15.3.2. Surgical Supply Stores

16. Erectile Dysfunction Devices Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Erectile Dysfunction Devices Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Erectile Dysfunction Devices Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Erectile Dysfunction Devices Market

20. China Erectile Dysfunction Devices Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Advin Health Care
  • 21.6. Alma Lasers Ltd.
  • 21.7. Augusta Medical Systems LLC
  • 21.8. Boston Scientific Corporation
  • 21.9. Coloplast A/S
  • 21.10. Comphya SA
  • 21.11. DirexGroup
  • 21.12. Dornier MedTech GmbH
  • 21.13. Futura Medical Developments Limited
  • 21.14. G.SURGIWEAR LTD.
  • 21.15. Implantica Management AG
  • 21.16. Medispec Ltd.
  • 21.17. OHHMED Medical Ltd.
  • 21.18. Owen Mumford Limited
  • 21.19. PROMEDON GmbH
  • 21.20. Rigicon, Inc.
  • 21.21. STORZ MEDICAL AG
  • 21.22. T.E. Inc.
  • 21.23. TIMM Medical
  • 21.24. Vacurect
  • 21.25. Zimmer MedizinSysteme GmbH
  • 21.26. ZSI Surgical Implants S.R.L.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY